EFFECT OF ADOPTING NEW CHOLESTEROL GUIDELINES IN ISRAEL

Published Dec 11, 2015
Tel Aviv, Israel - Statins for lowering LDL cholesterol levels ("bad cholesterol,") are the most commonly prescribed medications in the Western world. The guidelines of the American College of Cardiology (ACC) and the American Heart Association (AHA) for statin therapy to prevent cardiovascular disease have changed the older paradigm of treating patients based on LDL target levels to a more complicated risk assessment of atherosclerotic cardiovascular events. Adopting the ACC/AHA guidelines would increase substantially the already large number of patients on statins. In the study, “The potential effects of implementing the 2013 ACC/AHA cholesterol guidelines on the use of statins in a large health maintenance organization in Israel,” published in Value in Health Regional Issues, Volume 7, (September/October 2015), researchers aimed to assess the impact of adopting these guidelines on the number of patients requiring statins therapy in a large health maintenance organization in Israel, in which 30% of the nearly 800,000 adults aged 40y or above are currently treated with statins. Adopting the new guidelines would increase the proportion of statin treated members to 48% with a cost per cardiovascular event prevented estimated at $US 20,500.

Related Stories

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.

ISPOR Publishes a Statement of Principles Regarding Global Humanitarian Crisis

May 20, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced that it has published a Statement of Principles that outlines its position on the myriad global crises that are being faced by its members and stakeholders. The Statement of Principles is reflected below and is posted on the ISPOR website at www.ispor.org/StatementOfPrinciples.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×